{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:23:06Z","timestamp":1784776986758,"version":"3.55.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022789","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.breast.2025.104569","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:32:51Z","timestamp":1756362771000},"page":"104569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Palbociclib treatment in patients with HR+\/HER2\u2212 advanced or metastatic breast cancer and visceral metastasis: A systematic literature review"],"prefix":"10.1016","volume":"84","author":[{"given":"Julia C.","family":"Radosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara L\u00f3pez-Tarruella","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Dzieran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Glastetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Lingohr-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Pasupuleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib1","article-title":"Trends in 5-year cancer survival disparities by race and ethnicity in the US between 2002-2006 and 2015-2019","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.breast.2025.104569_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.clbc.2021.01.017","article-title":"Epidemiology of de novo metastatic breast cancer","volume":"21","author":"Daily","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"10.1016\/j.breast.2025.104569_bib4","first-page":"480","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2025.104569_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejca.2022.05.015","article-title":"Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - a retrospective analysis of a real world registry","volume":"172","author":"M\u00fcller","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.breast.2025.104569_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10549-024-07469-6","article-title":"Trends in HR+ metastatic breast cancer survival before and after CDK4\/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer","volume":"208","author":"Brufsky","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104569_bib7","article-title":"Real-world time trends in overall survival, treatments and patient characteristics in HR+\/HER2- metastatic breast cancer: an observational study of the SONABRE Registry","volume":"26","author":"Meegdes","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.breast.2025.104569_bib8","year":"2015"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.breast.2025.104569_bib11","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2025.104569_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.breast.2025.104569_bib13","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104569_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101541","article-title":"Pan-Asian adapted ESMO clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"8","author":"Im","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2025.104569_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"21","key":"10.1016\/j.breast.2025.104569_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215268","article-title":"Palbociclib combined with an aromatase inhibitor in patients with breast cancer with lung or liver metastases in US clinical practice","volume":"15","author":"Brufsky","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2025.104569_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.016","article-title":"Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016","volume":"129","author":"Deluche","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","article-title":"The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.breast.2025.104569_bib19","doi-asserted-by":"crossref","first-page":"27990","DOI":"10.18632\/oncotarget.15856","article-title":"Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.breast.2025.104569_bib20","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors' current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.breast.2025.104569_bib21","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.breast.2025.104569_bib23","author":"Wells"},{"key":"10.1016\/j.breast.2025.104569_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejca.2021.11.010","article-title":"Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive\/HER2-advanced breast cancer: GEICAM\/2014-12 (FLIPPER)","volume":"161","author":"Albanell","year":"2022","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.breast.2025.104569_bib25","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S1470-2045(19)30565-0","article-title":"Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial","volume":"20","author":"Park","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.breast.2025.104569_bib26","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1001\/jamaoncol.2021.4301","article-title":"Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor\u2013positive, ERBB2-negative advanced breast cancer: a randomized clinical trial","volume":"7","author":"Llombart-Cussac","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2025.104569_bib27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2022.08.012","article-title":"Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: primary results from PALOMA-4","volume":"175","author":"Xu","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2025.104569_bib28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2020.12.013","article-title":"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL","volume":"32","author":"Martin","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/mco.2022.2552","article-title":"Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: an experience at two cancer centers in Saudi Arabia","volume":"17","author":"Al-Foheidi","year":"2022","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13058-023-01678-5","article-title":"Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice","volume":"25","author":"Alves da Costa","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2025.104569_bib31","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3390\/curroncol28030209","article-title":"First-line treatment with a cyclin-dependent kinase 4\/6 inhibitor plus an aromatase inhibitor for metastatic breast cancer in Alberta","volume":"28","author":"Amaro","year":"2021","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101422","article-title":"234P real-world treatment patterns and outcomes of patients receiving palbociclib plus endocrine therapy in Spain: subgroup analysis based on age, sites and number of metastatic locations, menopausal status and dose received from PALBOSPAIN study","volume":"8","author":"Anton","year":"2023","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.breast.2025.104569_bib33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10549-019-05134-x","article-title":"Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK compassionate access programme experience","volume":"174","author":"Battisti","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.breast.2025.104569_bib34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11523-021-00826-1","article-title":"Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice","volume":"16","author":"Brufsky","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.breast.2025.104569_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.865292","article-title":"Real-world effectiveness of palbociclib plus letrozole vs letrozole alone for metastatic breast cancer with lung or liver metastases: flatiron database analysis","volume":"12","author":"Brufsky","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2025.104569_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.breast.2022.02.005","article-title":"Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: results from a population-based cohort study","volume":"62","author":"Cardoso Borges","year":"2022","journal-title":"Breast"},{"issue":"20","key":"10.1016\/j.breast.2025.104569_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14204981","article-title":"HER2-low status does not affect survival outcomes of patients with metastatic breast cancer (MBC) undergoing first-line treatment with endocrine therapy plus palbociclib: results of a multicenter, retrospective cohort study","volume":"14","author":"Carlino","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.breast.2025.104569_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108488","article-title":"Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer","volume":"24","author":"Cejuela","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","article-title":"Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2- metastatic breast cancer in US real-world clinical practice","volume":"23","author":"DeMichele","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s12885-022-09624-y","article-title":"Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study","volume":"22","author":"Eser","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.breast.2025.104569_bib41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/0284186X.2023.2194030","article-title":"A retrospective, non-interventional study of breast cancer patients diagnosed with ER+\/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark","volume":"62","author":"Garly","year":"2023","journal-title":"Acta Oncol"},{"issue":"12","key":"10.1016\/j.breast.2025.104569_bib42","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/ijc.33959","article-title":"Palbociclib plus endocrine therapy significantly enhances overall survival of HR+\/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: a large institutional study","volume":"150","author":"Ha","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2025.104569_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.759150","article-title":"Which clinicopathologic parameters suggest primary resistance to palbociclib in combination with letrozole as the first-line treatment for hormone receptor-positive, HER2-negative advanced breast cancer?","volume":"11","author":"Kim","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.breast.2025.104569_bib44","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.4143\/crt.2022.1543","article-title":"Efficacy of limited dose modifications for palbociclib-related grade 3 neutropenia in hormone receptor-positive metastatic breast cancer","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.breast.2025.104569_bib45","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/oncolo\/oyac089","article-title":"Real-world experience with CDK4\/6 inhibitors for metastatic HR+\/HER2- breast cancer at a single cancer center","volume":"27","author":"Knudsen","year":"2022","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.breast.2025.104569_bib46","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/curroncol29020089","article-title":"Real-world treatment patterns and clinical effectiveness of palbociclib plus an aromatase inhibitor as first-line therapy in advanced\/metastatic breast cancer: analysis from the US Syapse learning health network","volume":"29","author":"Law","year":"2022","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104569_bib47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4143\/crt.2020.451","article-title":"Real-world clinical data of palbociclib in Asian metastatic breast cancer patients: experiences from eight institutions","volume":"53","author":"Lee","year":"2021","journal-title":"Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.breast.2025.104569_bib48","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2217\/fon-2020-0744","article-title":"Treatment patterns and clinical outcomes of palbociclib-based therapy received in US community oncology practices","volume":"17","author":"Lin","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.breast.2025.104569_bib49","volume":"26","author":"Liu","year":"2020","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.breast.2025.104569_bib50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.breast.2020.11.005","article-title":"Palbociclib combined with endocrine therapy in heavily pretreated HR(+)\/HER2(-) advanced breast cancer patients: results from the compassionate use program in Spain (PALBOCOMP)","volume":"54","author":"Manso","year":"2020","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.breast.2025.104569_bib51","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.21873\/anticanres.16447","article-title":"Optimal treatment of hormone receptor-positive advanced breast cancer patients with palbociclib","volume":"43","author":"Morita","year":"2023","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1016\/j.breast.2025.104569_bib52","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.clinthera.2022.11.004","article-title":"Real-world treatment patterns and clinical outcomes associated with palbociclib combination therapy: a multinational, pooled analysis from the Ibrance real world insights study","volume":"44","author":"Mycock","year":"2022","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.breast.2025.104569_bib53","article-title":"Does proton pump inhibitors decrease the efficacy of palbociclib and ribociclib in patients with metastatic breast cancer?","volume":"59","author":"Odabas","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.breast.2025.104569_bib54","article-title":"Real-world outcomes of treating advanced breast cancer patients with palbociclib: a multicenter retrospective cohort study in Japan-the KBCOG-14 study","volume":"14","author":"Odan","year":"2020","journal-title":"Breast Cancer"},{"issue":"6","key":"10.1016\/j.breast.2025.104569_bib55","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1002\/jcp.27832","article-title":"Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience","volume":"234","author":"Pizzuti","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.breast.2025.104569_bib56","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.breast.2020.11.008","article-title":"Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer","volume":"54","author":"Porte","year":"2020","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.breast.2025.104569_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253722","article-title":"Efficacy and safety of palbociclib and ribociclib in patients with estrogen and\/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice","volume":"16","author":"Rath","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41523-022-00479-x","article-title":"Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+\/HER2- metastatic breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.breast.2025.104569_bib59","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10549-022-06574-8","article-title":"Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4\/6 inhibitors","volume":"194","author":"Schreier","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104569_bib60","doi-asserted-by":"crossref","first-page":"v114","DOI":"10.1093\/annonc\/mdz242.022","article-title":"Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: real-world progression-free survival analysis","volume":"30","author":"Torres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104569_bib61","article-title":"Real-world treatment patterns and clinical outcomes in patients receiving palbociclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in Argentina: the IRIS study","volume":"5","author":"Waller","year":"2019","journal-title":"J Glob Oncol"},{"issue":"17","key":"10.1016\/j.breast.2025.104569_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174360","article-title":"Effectiveness and safety of palbociclib plus endocrine therapy in patients with advanced breast cancer: a multi-center study in China","volume":"15","author":"Wu","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12885-023-10568-0","article-title":"Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib64","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1097\/CAD.0000000000001210","article-title":"The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis","volume":"33","author":"Zhang","year":"2022","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.breast.2025.104569_bib65","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221132926","article-title":"Early application of palbociclib plus endocrine therapy in HR+\/HER2- metastatic breast cancer: a better choice based on data from the Chinese population","volume":"21","author":"Zhang","year":"2022","journal-title":"Technol Cancer Res Treat"},{"issue":"21","key":"10.1016\/j.breast.2025.104569_bib66","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2217\/fon-2023-0176","article-title":"Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations","volume":"19","author":"Moser","year":"2023","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-023-11764-8","article-title":"Efficacy, safety, and predictive model of palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.breast.2025.104569_bib68","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-017-4623-8","article-title":"Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer","volume":"168","author":"du Rusquec","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104569_bib69","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920987651","article-title":"Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive\/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study","volume":"13","author":"Palumbo","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104569_bib70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10549-023-06911-5","article-title":"Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive\/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan breast Cancer Research Group-M07 (FUTURE trial)","volume":"199","author":"Watanabe","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104569_bib71","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221139678","article-title":"Real-world outcomes from use of CDK4\/6 inhibitors in the management of advanced\/metastatic breast cancer in Asia","volume":"14","author":"Low","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"22","key":"10.1016\/j.breast.2025.104569_bib72","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1002\/cam4.4767","article-title":"Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: a multicenter ambispective real-world study","volume":"11","author":"Shen","year":"2022","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.breast.2025.104569_bib73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/fon-2018-0531","article-title":"Treatment satisfaction in women receiving palbociclib combination therapies for advanced\/metastatic breast cancer","volume":"15","author":"Darden","year":"2019","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib74","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13058-016-0721-5","article-title":"Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2025.104569_bib75","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdx797","article-title":"Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases","volume":"29","author":"Turner","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101412","article-title":"Real-world effectiveness of palbociclib (Pal) plus an aromatase inhibitor (AI) vs AI alone in patients who have metastatic breast cancer (mBC) with lung or liver metastases","volume":"8","author":"Brufsky","year":"2023","journal-title":"ESMO Open"},{"issue":"15_suppl","key":"10.1016\/j.breast.2025.104569_bib77","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.2017.35.15_suppl.1039","article-title":"Palbociclib (PAL) + letrozole (L) as first-line (1L) therapy (tx) in estrogen receptor-positive (ER+)\/human epidermal growth factor receptor 2-negative (HER2\u2212) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups","volume":"35","author":"Finn","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104569_bib78","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104569_bib79","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.breast.2022.11.005","article-title":"Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor\u2012positive\/human epidermal growth factor receptor 2\u2012negative advanced breast cancer: post hoc analyses from PALOMA-2 and PALOMA-3","volume":"66","author":"Rugo","year":"2022","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.breast.2025.104569_bib80","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-020-05755-7","article-title":"Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+\/HER2- advanced breast cancer (PALOMA-1, TRIO-18)","volume":"183","author":"Finn","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104569_bib81","volume":"40","author":"Finn Rsr","year":"2022","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.breast.2025.104569_bib82","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and rulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104569_bib83","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2022.03.006","article-title":"Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study","volume":"168","author":"Martin","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13058-020-01263-0","article-title":"Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies","volume":"22","author":"Ettl","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"6","key":"10.1016\/j.breast.2025.104569_bib85","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib86","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/oncolo\/oyac205","article-title":"Palbociclib with fulvestrant or letrozole in endocrine-sensitive patients with HR-positive\/HER2-negative advanced breast cancer: a detailed safety analysis of the randomized PARSIFAL trial","volume":"28","author":"Di Cosimo","year":"2023","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41523-021-00222-y","article-title":"Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies","volume":"7","author":"Robertson","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2025.104569_bib88","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CMAR.S72592","article-title":"Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options","volume":"7","author":"Harb","year":"2015","journal-title":"Cancer Manag Res"},{"issue":"23","key":"10.1016\/j.breast.2025.104569_bib89","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.24.00144","article-title":"Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"42","author":"Lu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104569_bib90","series-title":"Primary results of the randomized phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-\/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study","year":"2024"},{"issue":"1","key":"10.1016\/j.breast.2025.104569_bib91","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10549-023-07035-6","article-title":"CDK4\/6 inhibitors versus weekly paclitaxel for treatment of ER+\/HER2- advanced breast cancer with impending or established visceral crisis","volume":"202","author":"Behrouzi","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.104569_bib92","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.1047","article-title":"Efficacy of CDK4\/6i in the visceral crisis setting: result from a real-world database","volume":"39","author":"Dawood","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:02:43Z","timestamp":1772877763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625005867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":89,"alternative-id":["S0960977625005867"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104569","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palbociclib treatment in patients with HR+\/HER2\u2212 advanced or metastatic breast cancer and visceral metastasis: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104569"}}